Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 14/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096625 | 0.93 | P2RX1 (0.44) | RXFP1LMNAMAPT | |
| SCHEMBL6096112 | 0.91 | PPARA (0.50) | LMNACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6097354 | 0.88 | P2RX1 (0.53) | RXFP1SMN1; SMN2 | |
| SCHEMBL6097613 | 0.86 | KMT2A (0.47) | MAPTSMN1; SMN2MEN1CYP1A2POLB | |
| SCHEMBL6095894 | 0.85 | CA1 (0.42) | LMNAMAPTSMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL6095797 | 0.84 | CA1 (0.42) | RXFP1LMNAMAPTSMN1; SMN2CYP1A2 | |
| SCHEMBL6095913 | 0.84 | MEN1 (0.45) | LMNAMAPTSMN1; SMN2MEN1CYP1A2 | |
| SCHEMBL6098348 | 0.84 | CCR5 (0.48) | RXFP1LMNAMEN1CYP1A2POLB | |
| SCHEMBL6095754 | 0.83 | GAA (0.41) | RXFP1LMNAMAPTSMN1; SMN2MEN1 | |
| SCHEMBL6095101 | 0.83 | TOP1 (0.44) | MAPTSMN1; SMN2MEN1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | claimed |
| US-7064124-B2 | NF-κB inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-06-20 | — | — | US | disclosed |
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-06-24 | — | — | US | disclosed |
| EP-1314712-A1 | NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT | Daiichi Suntory Pharma Co., Ltd. (JP) | 2003-05-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122244-A1 | Nf-kappa b inhibitor containing substituted benzoic acid derivative as active ingredient | NFKBIA, NFKB1, IKBKB | RXFP1 4462/4885LMNA 1361/4885MAPT 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.